RT Journal Article SR Electronic T1 Synaptic loss in behavioural variant frontotemporal dementia revealed by [11C]UCB-J PET JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.30.22270123 DO 10.1101/2022.01.30.22270123 A1 Malpetti, Maura A1 Jones, P. Simon A1 Cope, Thomas E. A1 Holland, Negin A1 Naessens, Michelle A1 Rouse, Matthew A. A1 Savulich, George A1 Fryer, Tim D. A1 Hong, Young T. A1 Sephton, Selena Milicevic A1 Aigbirhio, Franklin I. A1 O’Brien, John T. A1 Rowe, James B. YR 2022 UL http://medrxiv.org/content/early/2022/02/01/2022.01.30.22270123.abstract AB Synaptic loss is an early feature of neurodegenerative disease models, and is often severe in post mortem clinical studies, including frontotemporal dementia. Positron emission tomography (PET) imaging with radiotracers that bind to synaptic vesicle glycoprotein 2A enables quantification of synapses in vivo. This study used [11C]UCB-J PET in people with behavioural variant frontotemporal dementia (bvFTD), testing the hypothesis that synaptic loss is severe and related to clinical severity. We performed a cross-sectional observational study of bvFTD, versus healthy controls, in which participants underwent neurological examination, neuropsychological assessment, magnetic resonance imaging (MRI) and [11C]UCB-J PET. Patients were recruited from the Cambridge Centre for Frontotemporal Dementia at the University of Cambridge, and healthy volunteers from the UK National Institute for Health Research Join Dementia Research register. Eleven people with a clinical diagnosis of probable bvFTD and 25 age- and sex-matched healthy controls were included. All participants underwent dynamic [11C]UCB-J PET imaging, structural MRI and a neuropsychological battery, including the Addenbrooke’s cognitive examination (ACE-R), and INECO frontal screening (IFS). General linear models were used to compare [11C]UCB-J binding potential maps between groups, and correlate synaptic density with cognitive performance and clinical features in patients. Group-comparison and correlation analyses were also performed using partial-volume corrected [11C]UCB-J binding potential from regions of interest (ROIs). Patients with bvFTD showed severe synaptic loss compared to controls. In particular, [11C]UCB-J binding was significantly reduced bilaterally in medial and dorsolateral frontal regions, inferior frontal gyri, anterior and posterior cingulate gyrus, insular cortex and medial temporal lobe. Synaptic loss in the left frontal and cingulate regions correlated significantly with cognitive impairments as assessed with ACE-R and IFS. Results from ROI-based analyses mirrored the voxel-wise results. In keeping with preclinical models, and human post mortem data, there is widespread frontotemporal loss of synapses in symptomatic bvFTD, in proportion to disease severity. [11C]UCB-J PET could support translational studies and experimental medicines strategies for new disease-modifying treatments for neurodegeneration.Competing Interest StatementUnrelated to this work, JTO has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai and Novo Nordisk, and has acted as a consultant for Biogen and Roche, and has received research support from Alliance Medical and Merck. JBR is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, UCB, Astex, Curasen, Wave, SVHealth, and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK.Funding StatementThis study was co-funded by the Wellcome Trust (220258), Race Against Dementia Alzheimer's Research UK (ARUK-RADF2021A-010), the Cambridge University Centre for Parkinson-Plus (RG95450), the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014, the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care), Medical Research Council (SUAG/051 G101400), and the Association of British Neurologists, Patrick Berthoud Charitable Trust (RG99368). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research protocol was approved by the Cambridge Research Ethics Committee (18/EE/0059) and the Administration of Radioactive Substances Advisory Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data may be shared upon request to the corresponding or senior author from a qualified investigator for non-commercial use, subject to restrictions according to participant consent and data protection legislation.